Finance

Lists
Outlook: 56.9% bullish·10.3% bearish
Go to analysis
ISRG:NASDAQ
Intuitive Surgical Inc
$445.88
-1.27%
(-5.75) 1D
$442.59
-0.74% (-3.29)
Pre-market
Closed: Oct 27, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ISRG...
Open
$451.63
High
$451.63
Low
$443.85
Mkt. cap
154.56B
Avg. vol.
2.35M
Volume
1.15K
P/E ratio
53.94
52-wk high
$603.88
52-wk low
$328.57
EPS
$8.27
Beta
1.46
Shares outstanding
346.64M
No. of employees
17K
Open
$451.63
High
$451.63
Low
$443.85
Mkt. cap
154.56B
Avg. vol.
2.35M
Volume
1.15K
P/E ratio
53.94
52-wk high
$603.88
52-wk low
$328.57
EPS
$8.27
Beta
1.46
Shares outstanding
346.64M
No. of employees
17K
News stories
From web sources and news partners
Profile
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world. Intuitive Surgical first appeared on the Fortune 500 in 2024 at number 497; in 2025 the company rose to number 459 overall and ranked 43rd within the healthcare sector. Wikipedia
About Intuitive Surgical Inc
CEODavid J. Rosa
Employees17K
Founded1995
HeadquartersSunnyvale, California, United States
SectorMedical device
Website-
Analyst ratings
Based on 20 analysts giving stock ratings to ISRG in the past 3 months
Strong buy
Buy
18
Hold
2
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for ISRG in the last 3 months.
Highest
Current $445.88
$685.00 (+53.63%)
Average
$498.26 (+11.75%)
Lowest
$391.00 (-12.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Buy
Reiterated
$470.00
+5.4%
10/21/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
$503.00
+12.8%
10/21/2026
Jayson Bedford
Raymond James
Buy
Maintained
$480.00
+7.7%
10/21/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
$500.00
+12.1%
10/21/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$550.00
+23.4%
10/21/2026
Lee Hambright
Bernstein
Buy
Maintained
$685.00
+53.6%
10/21/2026
Vik Chopra
BMO Capital
Buy
Reiterated
$518.00
+16.2%
10/20/2026
Kendall Au
RBC Capital
Buy
Reiterated
$550.00
+23.4%
10/20/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$550.00
+23.4%
10/20/2026
Adam Maeder
Piper Sandler
Buy
Reiterated
$470.00
+5.4%
10/21/2026
Robbie Marcus
J.P. Morgan
Buy
Reiterated
$475.00
+6.5%
10/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
$400.00
-10.3%
10/21/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$486.00
+9%
10/21/2026
Joanne Wuensch
Citi
Buy
Maintained
$500.00
+12.1%
10/20/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$454.00
+1.8%
10/20/2026
David Rescott
Robert W. Baird
Buy
Maintained
$550.00
+23.4%
10/21/2026
Hans Engel
Erste Group
Buy
Upgraded
-
-
10/21/2026
Christopher Pasquale
Barclays
Buy
Maintained
$500.00
+12.1%
10/21/2026
Joshua Buchalter
TD Cowen
Buy
Maintained
$485.00
+8.8%
10/19/2026
Patrick Wood
UBS
Buy
Maintained
$500.00
+12.1%
10/13/2026
Matt Miksic
Barclays
Buy
Maintained
$485.00
+8.8%
10/07/2026
Mathew Blackman
TD Cowen
Buy
Maintained
$485.00
+8.8%
08/03/2026
Helen Fang
HSBC
Hold
Downgraded
$391.00
-12.3%
07/30/2026
Unknown Analyst
Mirae Asset
Buy
Upgraded
-
-
07/21/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
07/17/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$510.00
+14.4%
07/17/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$518.00
+16.2%
07/09/2026
Vijay Kumar
Evercore ISI
Hold
Maintained
$430.00
-3.6%
07/06/2026
David Roman
Goldman Sachs
Buy
Reiterated
$558.00
+25.1%
06/15/2026
Imron Zafar
Deutsche Bank
Sell
Maintained
$366.00
-17.9%
06/02/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
05/05/2026
Unknown Analyst
Jefferies
Hold
Reiterated
$515.00
+15.5%
04/22/2026
Nico Chen
DBS
Hold
Maintained
$480.00
+7.7%
03/18/2026
Danielle Antalffy
UBS
Hold
Reiterated
$550.00
+23.4%
03/17/2026
Last report
Oct 20, 2026
Fiscal period
Q3 2026
$3.00 / $2.64
+13.61%beat
Revenue / Est. (USD)
3.05B / 2.91B
+4.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.87B
2.77B
2.89B
3.05B
Cost of goods sold
961.90M
940.30M
931.90M
992.20M
Cost of revenue
961.90M
940.30M
931.90M
992.20M
Research and development expenses
352.90M
361.90M
370.60M
408.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
687.10M
613.30M
617.90M
633.40M
Operating expense
1.04B
975.20M
988.50M
1.04B
Total operating expenses
2.00B
1.92B
1.92B
2.03B
Operating income
864.30M
855.30M
971.90M
1.01B
Other non operating income
-
-
-
-
EBT including unusual items
955.60M
940.40M
1.05B
668.40M
EBT excluding unusual items
950.90M
939.80M
1.05B
1.09B
Income tax expense
156.10M
114.40M
231.40M
144.00M
Effective tax rate
16.34%
12.16%
21.94%
21.54%
Other operating expenses
-
-
-
-
Net income
794.80M
821.50M
818.10M
522.80M
Net profit margin
27.73%
29.65%
28.29%
17.15%
Earnings per share
2.53
2.50
2.80
3.00
Interest and investment income
77.50M
85.70M
81.10M
92.10M
Interest expense
-
-
-
-
Net interest expenses
77.50M
85.70M
81.10M
92.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.02B
1.06B
1.20B
1.23B
Gain or loss from assets sale
13.70M
-7.90M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps